Neuhaus-Steinmetz U, Glaab T, Daser A, Braun A, Lommatzsch M, Herz U, Kips J, Alarie Y, Renz H
Institute of Laboratory Medicine and Pathobiochemistry, Charité Campus Virchow Clinic, Berlin, Germany.
Int Arch Allergy Immunol. 2000 Jan;121(1):57-67. doi: 10.1159/000024298.
Mouse models have been established mirroring key features of human bronchial asthma including airway hyperresponsiveness (AHR). Acute airway obstruction in response to an allergen challenge, however, remains to be demonstrated in these models.
A mouse model of allergic lung inflammation was employed to analyze the development of specific (allergen-induced) and nonspecific (methacholine-induced) airway obstruction.
Mice were sensitized to ovalbumin (OVA) and challenged with OVA aerosol twice each week during four weeks. Changes in lung functions were determined by noninvasive head-out body plethysmography. The development of acute airway obstruction after OVA challenge and AHR after methacholine aerosol application were assessed by a decrease in the mid-expiratory flow rate (EF(50)).
Two airway challenges were sufficient to induce AHR (5.7 vs. 15 mg/ml methacholine). Further OVA challenges reduced the baseline EF(50) from 1.85 to 1.20 ml/s (4th week) and induced acute airway obstruction. The OVA-induced obstruction was maximal in the 4th week (EF(50) = 0.91 ml/s).
The development of acute airway obstruction in allergen-sensitized mice was demonstrated by means of head-out body plethysmography. In our model, AHR was observed before the development of airway obstruction.
已建立反映人类支气管哮喘关键特征(包括气道高反应性[AHR])的小鼠模型。然而,在这些模型中,对过敏原激发的急性气道阻塞仍有待证实。
采用变应性肺部炎症小鼠模型分析特异性(过敏原诱导)和非特异性(乙酰甲胆碱诱导)气道阻塞的发展情况。
小鼠用卵清蛋白(OVA)致敏,并在四周内每周两次用OVA气雾剂激发。通过无创头部外露式体积描记法测定肺功能变化。通过呼气中期流速(EF(50))降低评估OVA激发后急性气道阻塞的发展情况以及乙酰甲胆碱气雾剂应用后AHR情况。
两次气道激发足以诱导AHR(乙酰甲胆碱浓度为5.7与15 mg/ml时)。进一步的OVA激发使基线EF(50)从1.85降至1.20 ml/s(第4周),并诱导急性气道阻塞。OVA诱导的阻塞在第4周时最大(EF(50)=0.91 ml/s)。
通过头部外露式体积描记法证实了过敏原致敏小鼠急性气道阻塞的发展情况。在我们的模型中,在气道阻塞发展之前观察到了AHR。